Kamada (company)

Kamada Ltd. is a biopharmaceutical company specializing in the development, manufacture and marketing of proteins as pharmaceuticals. The company's headquarters and laboratories are located in the park of Kiryat Weizmann Institute of Science in Rehovot. The production facility is located in Kibbutz Beit Kama.

Kamada Ltd.
TypePublic
TASE: KMDA
Nasdaq: KMDA
IndustryPharmaceutical
Founded1990 (1990)
HeadquartersRehovot, Israel
Key people
Leon Recanati, Chairman of the Board
Amir London , CEO
ProductsGlassia, KamRAB, KamRho
Number of employees
316 (2001)
Websitewww.kamada.com

The company produces about 10 injectable and marketed drugs in more than 15 countries.

History

Kamada was founded in 1990 by David Tzur, Ralph Hahn and Kamapharam Ltd., which was wholly owned by Kibbutz Beit Kama, until then Kamapharam was producing albumin, and its production facilities were acquired in full by Kamada In 1999, (35%) to a company owned by Hahn and another investor for $2.5 million. Hahn and Tzur headed the company by the beginning of 2013. The company completed its first public offering in 2005 on the Tel Aviv Stock Exchange.[1]

Today, the company specializes in the development, manufacture and marketing of proteins, especially for orphan diseases. The company produces about 10 injectable and marketed drugs in more than 15 countries around the world.[2]

Kamada is a member of the Biomed index on the Tel Aviv Stock Exchange, and as of December 2012, its shares were included in the Tel Aviv 100 index.[3]

In 2012, the company was ranked 456 among the 500 fastest growing companies in Europe (and 15th in Israel) according to the Deloitte Index, based on their income in 2007–2011.[4]

In May 2014, the company announced that it had not met the target set for the trial for a hereditary emphysema in inhalation.[5] Following the failure of the experiment, the company's market value fell within a year from $500 million to $150 million.[6]

Products

Alpha-1 anti-trypsin for infusion (AAT IV)

Kamada's flagship product is Glassia, approved by the FDA to treat alpha 1-antitrypsin deficiency. The active ingredient in the drug is the protein alpha-1 antitrypsin, for patients with a genetic deficiency in that protein. The firm has a strategic agreement with Baxter for the marketing, distribution and licensing of the drug in the United States.[7][8]

Production of immunoglobulins

The company has developed a technological platform for the production of specific immunoglobulins (IgG's). It produces a specific antibody against the rabies virus, and a product for the treatment of HDN - disease of the newborn hemolytic (Hemolytic Disease of the Newborn) - a disease caused from Rh negative in the fetus.

The company cooperates with the Israeli Ministry of Health, in the framework of which it established a GMP standard for the production of serum against snake venom. The product is manufactured from the serum of hyper-immune horses .[9]

The company has a strategic agreement with Kedrion Pharmaceuticals for the development and marketing of the KamRab rabies immunoglobulin in the United States.[10]

See also

References
  1. "Prospectus of a public offering dated August 18, 2005". TASE (in Hebrew). Retrieved 2019-05-15.
  2. "Kamada Company Profile". Retrieved May 15, 2019.
  3. Ben-Simon, Guy (2012-12-10). "Kamada enters Tel Aviv 100". כלכליסט - www.calcalist.co.il (in Hebrew). Retrieved 2019-05-15.
  4. "Fast 500 EMEA 2012 winners | Deloitte LLP". 2013-01-23. Archived from the original on 2013-01-23. Retrieved 2019-05-15.
  5. צליק, ניר (2014-05-16). "Kamada did not meet the central goal of the experiment in inhalation for hereditary emphysema patients". כלכליסט - www.calcalist.co.il (in Hebrew). Retrieved 2019-05-15.
  6. צליק, ניר (2015-05-05). ""The value of a company like Kamada is $ 1 billion"". כלכליסט - www.calcalist.co.il (in Hebrew). Retrieved 2019-05-15.
  7. Research, Center for Biologics Evaluation and (2019-04-09). "GLASSIA". FDA.
  8. "Kamada and Baxter Enter into a Strategic Agreement for the Distribution and Manufacture of Intravenous Liquid AAT to Treat Alpha-1 Antitrypsin Deficiency in the US". www.businesswire.com. 2010-08-24. Retrieved 2019-05-15.
  9. גביזון, יורם (2011-08-30). "קמהדע תמכור למדינה נסיוב נגד ארס נחשים ב-35 מיליון שקל בעשור הקרוב". TheMarker. Retrieved 2019-05-15.
  10. "Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14". NASDAQ.com. Retrieved 2019-05-15.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.